Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Completed phase 3 CALLA trial (770 actual enrollment) of durvalumab plus chemoradiotherapy versus chemoradiotherapy alone in locally advanced cervical cancer. Primary clinical result: Monk et al., Lancet Oncol 2023 (PMID 38039991), negative for investigator-assessed PFS in a biomarker-unselected ITT population (HR 0.84, 95% CI 0.65–1.08, P=0.17). ctDNA analysis is correlative, not a treatment-assignment biomarker. ClinicalTrials.gov API v2 on 13 Nov 2026: COMPLETED, start 2019-02-15, primary completion 2022-01-20, completion 2023-07-03, last update 2024-07-26, lead sponsor AstraZeneca.

AstraZeneca